UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Utilizing Hydrazine and Hydrogen as Reducing Agents to Control the Nanoscale Surface Morphology of the Palladium Thin Films

Physica status solidi. A, Applications and materials science, 2023-09, Vol.220 (18), p.n/a

2023

Volltextzugriff (PDF)

FRI0451 Secukinumab Provides Rapid and Sustained Reductions in Dactylitis and Enthesitis in Patients with Psoriatic Arthritis: Analysis of Data from The Phase 3 Randomised, Multicentre, Double-Blind, Placebo-Controlled Future 2 Study

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.599

2016

Volltextzugriff (PDF)

OP0306 Subcutaneous secukinumab inhibits radiographic progression in psoriatic arthritis: analysis by prior anti-tnf therapy and concomitant methotrexate use

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.199

2018

Volltextzugriff (PDF)

SAT0335 Secukinumab provides rapid and sustained resolution of enthesitis in psoriatic arthritis patients: pooled analysis of two phase 3 studies, future 2 and future 3

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1032

2018

Volltextzugriff (PDF)

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies

Annals of the Rheumatic Diseases, 2011-10, Vol.70 (10), p.1713-1718

2011

Volltextzugriff (PDF)

SAT0579 Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials (Future 1 and Future 2)

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.870-871

2015

Volltextzugriff (PDF)

THU0442 Reduction in Fatigue in Patients with Active Psoriatic Arthritis Are Sustained over 2 Years: Long-Term Results of Two Phase 3 Studies with Secukinumab

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.351-351

2016

Volltextzugriff (PDF)

THU0448 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab Up To 48 Weeks Using A Matching-Adjusted Indirect Comparison

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.353-354

2016

Volltextzugriff (PDF)

FRI0448 Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Psoriatic Arthritis: 2-Year Efficacy and Safety Results from The Phase 3 Randomised, Double-Blind, Placebo-Controlled Trial, Future 1

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.598-598

2016

Volltextzugriff (PDF)

THU0437 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Licensed Biologics and Apremilast from A Network Meta-Analysis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.348-349

2016

Volltextzugriff (PDF)

FRI0463 Secukinumab Improves Minimal Disease Activity Response Rates in Patients with Active Psoriatic Arthritis: Data from The Randomized Phase 3 Study, Future 2

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.605-605

2016

Volltextzugriff (PDF)

Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions

Annals of the rheumatic diseases, 2004-05, Vol.63 (5), p.588-590

2004

Volltextzugriff (PDF)

AB0505 Enhanced improvement in physical functioning with secukinumab treatment among RA patients: An application of IRT methodology

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.666-666

2013

Volltextzugriff (PDF)

AB0507 Health-related quality of life (HRQOL) benefits associated with reductions in disease activity and pain severity among rheumatoid arthritis (RA) patients treated with secukinumab

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.667-667

2013

Volltextzugriff (PDF)

AB0504 Association between health-related quality of life (HRQOL) and ACR improvement among rheumatoid arthritis (RA) patients treated with secukinumab

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.666-666

2013

Volltextzugriff (PDF)

AB0582 Improvements in health-related quality of life (HRQOL) in patients with rheumatoid arthritis (RA) receiving secukinumab: Results of a dose-finding study

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.671-671

2013

Volltextzugriff (PDF)

AB0506 Enhanced improvement in fatigue from RA treatment with secukinumab: An application of IRT methodology

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.667-667

2013

Volltextzugriff (PDF)

AB0738 Secukinumab Reduces Hscrp Levels in Subjects with Moderate-To-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis: A Sub-Analysis from the Phase 3 Erasure Study

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.1047-1048

2014

Volltextzugriff (PDF)

Cattle manure effects on structural stability and water retention capacity of a granitic sandy soil in Zimbabwe

Soil & tillage research, 2001-11, Vol.62 (3), p.157-162

2001

Volltextzugriff (PDF)

THU0418 Secukinumab Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from the Phase 3 Future 2 Study

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.349-350

2015

Volltextzugriff (PDF)

THU0411 Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-IR Patients with Psoriatic Arthritis: Results of a Phase 3 Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.345-346

2015

Volltextzugriff (PDF)

THU0433 Secukinumab Improves Physical Function, Quality of Life, Fatigue and Work Productivity in Patients with Active Psoriatic Arthritis in Future 2, A Phase 3 Trial

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.356-356

2015

Volltextzugriff (PDF)

THU0421 Secukinumab is Effective in Reducing Dactylitis and Enthesitis Using Multiple Measures in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.351-351

2015

Volltextzugriff (PDF)

Anti-TNF-α therapies: they are all the same (aren't they?)

Rheumatology (Oxford, England), 2005-03, Vol.44 (3), p.271-273

2005

Volltextzugriff (PDF)

Effects of Palladium Chloride Concentration on the Nanoscale Surface Morphology of Electroless Deposited Palladium Thin Film

Journal of the Electrochemical Society, 2021-05, Vol.168 (5), p.56522

2021

Volltextzugriff (PDF)

1 – 25 von 1.809

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.081)
Mit Volltextzugriff
(1.421)

Publikationsform

7 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(572)
Life Sciences & Biomedicine
(376)
Humans
(226)
Social Sciences
(214)
Technology
(166)
Female
(156)
Engineering
(145)
Zimbabwe
(126)
Male
(125)
Adult
(79)
Adolescent
(74)
Engineering, Manufacturing
(70)
South Africa
(65)
Public, Environmental & Occupational Health
(63)
Biological And Medical Sciences
(58)
Middle Aged
(55)
Psychology
(53)
Public Health
(53)
Science & Technology - Other Topics
(52)
Covid-19
(50)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Utilizing Hydrazine and Hydrogen as Reducing Agents to Control the Nanoscale Surface Morphology of the Palladium Thin Films

FRI0451 Secukinumab Provides Rapid and Sustained Reductions in Dactylitis and Enthesitis in Patients with Psoriatic Arthritis: Analysis of Data from The Phase 3 Randomised, Multicentre, Double-Blind, Placebo-Controlled Future 2 Study

OP0306 Subcutaneous secukinumab inhibits radiographic progression in psoriatic arthritis: analysis by prior anti-tnf therapy and concomitant methotrexate use

SAT0335 Secukinumab provides rapid and sustained resolution of enthesitis in psoriatic arthritis patients: pooled analysis of two phase 3 studies, future 2 and future 3

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies

SAT0579 Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials (Future 1 and Future 2)

THU0442 Reduction in Fatigue in Patients with Active Psoriatic Arthritis Are Sustained over 2 Years: Long-Term Results of Two Phase 3 Studies with Secukinumab

THU0448 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab Up To 48 Weeks Using A Matching-Adjusted Indirect Comparison

FRI0448 Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Psoriatic Arthritis: 2-Year Efficacy and Safety Results from The Phase 3 Randomised, Double-Blind, Placebo-Controlled Trial, Future 1

THU0437 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Licensed Biologics and Apremilast from A Network Meta-Analysis

FRI0463 Secukinumab Improves Minimal Disease Activity Response Rates in Patients with Active Psoriatic Arthritis: Data from The Randomized Phase 3 Study, Future 2

Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions

AB0505 Enhanced improvement in physical functioning with secukinumab treatment among RA patients: An application of IRT methodology

AB0507 Health-related quality of life (HRQOL) benefits associated with reductions in disease activity and pain severity among rheumatoid arthritis (RA) patients treated with secukinumab

AB0504 Association between health-related quality of life (HRQOL) and ACR improvement among rheumatoid arthritis (RA) patients treated with secukinumab

AB0582 Improvements in health-related quality of life (HRQOL) in patients with rheumatoid arthritis (RA) receiving secukinumab: Results of a dose-finding study

AB0506 Enhanced improvement in fatigue from RA treatment with secukinumab: An application of IRT methodology

AB0738 Secukinumab Reduces Hscrp Levels in Subjects with Moderate-To-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis: A Sub-Analysis from the Phase 3 Erasure Study

Cattle manure effects on structural stability and water retention capacity of a granitic sandy soil in Zimbabwe

THU0418 Secukinumab Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from the Phase 3 Future 2 Study

THU0411 Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-IR Patients with Psoriatic Arthritis: Results of a Phase 3 Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

THU0433 Secukinumab Improves Physical Function, Quality of Life, Fatigue and Work Productivity in Patients with Active Psoriatic Arthritis in Future 2, A Phase 3 Trial

THU0421 Secukinumab is Effective in Reducing Dactylitis and Enthesitis Using Multiple Measures in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

Anti-TNF-α therapies: they are all the same (aren't they?)

Effects of Palladium Chloride Concentration on the Nanoscale Surface Morphology of Electroless Deposited Palladium Thin Film

Suchergebnisse filtern